Please provide your email address to receive an email when new articles are posted on . “The cell-free DNA is the first blood-based test with performance that is comparable to current guideline ...

A novel, blood-based test developed using fragmentomic features of cell-free DNA (cfDNA) detects colorectal cancer (CRC) with a 90.4% sensitivity and shows consistent performance across stages and ...

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...

cf-bDNA testing can reduce CRC incidence and mortality but is less effective and more costly than colonoscopy and FIT. The test may increase screening participation among those who avoid traditional ...

BRISBANE, Calif., May 27, 2026 /PRNewswire/ -- Freenome, an early cancer detection company developing blood-based screening tests, welcomes the inclusion of blood-based testing in the American Cancer ...

Freenome has entered an exclusive licence agreement with Exact Sciences, granting the latter the rights to commercialise Freenome's blood-based colorectal cancer (CRC) screening test in the US. Exact ...